Medpace (MEDP)

• Market cap: $14B
• 1 day: 1.44%
• 5 days: 4.21%
• 1 month: 7.54%
• 3 months: 67.1%
• 6 months: 52.55%
• Year to date: 48.72%
• 1 year: 40.37%
• 5 years: 327.4%
• 10 years: 1,691.4%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Employees: 6,000

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

35% more first-time investments, than exits

New positions opened: 73 | Existing positions closed: 54

8.33% more ownership

Funds ownership: 83.17% [Q1] → 91.51% (+8.33%) [Q2]

7% more capital invested

Capital invested by funds: $7.72B [Q1] → $8.26B (+$546M) [Q2]

2% more funds holding

Funds holding: 578 [Q1] → 591 (+13) [Q2]

3% less repeat investments, than reductions

Existing positions increased: 220 | Existing positions reduced: 226

14% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]

49% less call options, than puts

Call options by funds: $17.1M | Put options by funds: $33.2M

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $305
• Avg. target: $435
• High target: $510

9 analyst ratings

• positive: 1 11%
• neutral: 6 67%
• negative: 2 22%

Jefferies David Windley	$450	Hold Maintained	9 Sep 2025
Rothschild & Co Jamie Clark	$474	Neutral Downgraded	3 Sep 2025
UBS Dan Leonard	$305	Sell Downgraded	29 Jul 2025
Mizuho Ann Hynes	$510	Outperform Maintained	25 Jul 2025
Truist Securities Jailendra Singh	$436	Hold Maintained	23 Jul 2025